Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
References New England Journal of Medicine - Retatrutide Phase 2 Trial - Primary efficacy and safety data for retatrutide New England Journal of Medicine - SURMOUNT-1 Trial - Tirzepatide obesity trial results FDA - Zepbound (Tirzepatide) Approval - FDA approval information for tirzepatide ClinicalTrials.gov - Retatrutide Studies - Ongoing Phase 3 clinical trials ClinicalTrials.gov - Retatrutide Phase 3 trials Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice
These effects were completely inhibited by pasireotide
Higher Success Rates Compared to Placebo In one major trial[6], 34% of men using bremelanotide reported clear improvement, including the ability to achieve and maintain an erection for intercourse
This allowed them to process data at a scale that would have been impossible with manual review
